Skip to content

Nexus Venture Partners

Venture capital

Venture capital firm investing in India and the US.

Minutes holds 2 deals naming Nexus Venture Partners.

As an investor

2 deals Minutes has recorded
Rounds recorded
2
Since 2023
Led
0
0% of its rounds
Companies recorded
1
Exits recorded
1
1 IPO

By stage

Rounds recorded since 2023

  • Series B1
  • Series B extension1

By industry

Rounds recorded since 2023; a round in two industries counts in each

  • Healthcare2
  • Technology2

By region

Rounds recorded since 2023, by the company's headquarters region

  • Region not recorded2

Deals Minutes has recorded

Rounds naming this investor that Minutes has recorded
DateCompanyRoundAmountRoleOutcome
18 June 2024Iambic Therapeutics HealthcareSeries B extension$50MJoinedListed · Oct 2026
3 October 2023Iambic Therapeutics HealthcareSeries B$100MJoinedListed · Oct 2026

2 of 2

Exits

Each exit, with the rounds Nexus Venture Partners joined before it

Iambic Therapeutics · Listed · 14 October 2026

Nexus Venture Partners joined: Series B → Series B extension

Returns not shown: Minutes does not hold stake sizes unless a party discloses them.

Co-investors in these rounds

Abingworth2 rounds togetherJun 18, 2024
Illumina Ventures2 rounds togetherJun 18, 2024
Coatue2 rounds togetherJun 18, 2024
Mubadala Capital1 round togetherJun 18, 2024
Exor Ventures1 round togetherJun 18, 2024
Qatar Investment Authority1 round togetherJun 18, 2024
Tao Capital Partners1 round togetherJun 18, 2024
Ascenta Capital1 round togetherOct 03, 2023

8 more in Minutes

Deals in Minutes

Deals naming Nexus Venture Partners
CompanyDealAmountCounterpartiesDate ↓Status
Iambic TherapeuticsBiotechFundingSeries B extension$50MLed by Mubadala Capital, Exor VenturesWith Qatar Investment Authority, Abingworth +418 Jun 2024Closed
Iambic TherapeuticsBiotechFundingSeries B$100MLed by Ascenta Capital, AbingworthWith NVIDIA, Illumina Ventures +93 Oct 2023Closed
Showing 1–2 of 2

Nexus Venture Partners

No developments name Nexus Venture Partners yet.